Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells

Blood

Volumn 113, Issue 8, 2009, Pages 1699-1709

  Alfano, Massimo ^a,e   Mariani, Samanta A ^a   Elia, Chiara ^a   Pardi, Ruggero ^b,c   Blasi, Francesco ^b,c,d   Poli, Guido ^a,c  

^a AIDS Immunopathogenesis Unit   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^e P2 P3 Laboratories   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; BETA2 INTEGRIN; CD11B ANTIGEN; CD18 ANTIGEN; CYTOKINE; FIBRINOGEN; INTEGRIN; LIGAND; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; PHORBOL 13 ACETATE 12 MYRISTATE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; VIRION; VIRUS EXPRESSION;

EID: 61849130031     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-138412     Document Type: Article

References (76)

1. Dano K,Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139-266.
2. Blasi F, Vassalli JD, Dano K. Urokinase-type plas-minogen activator: proenzyme, receptor, and inhibitors. J Cell Biol. 1987;104:801-804.
3. Gyetko MR, Libre EA, Fuller JA, Chen GH, Toews G. Urokinase is required for T lymphocyte proliferation and activation in vitro. J Lab Clin Med. 1999;133:274-288.
4. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 inte-grins in vivo. J Exp Med. 1998;188:1029-1037.
5. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932-943.
6. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol. 2000;12:613-620.
7. Blasi F. uPA, uPAR, PAI-1: key intersection of pro-teolytic, adhesive and chemotactic highways? Immunol Today. 1997;18:415-417.
8. Shushakova N, Tkachuk N, Dangers M, et al. Urokinase-induced activation of the gp130/Tyk2/ Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Sci. 2005;118: 2743-2753.
9. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol. 1997;9:714-724.
10. Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol. 2000;12:621-628.
11. Sidenius N, Sier CF, Ullum H, et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood. 2000;96:4091-4095.
12. Ostrowski SR, Katzenstein TL, Pedersen M, et al. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy. Scand J Immunol. 2006;63:478-486.
13. Sporer B, Koedel U, Popp B, Paul R, Pfister HW. Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients. J Neuroimmunol. 2005;163:190-194.
14. Cinque P, Nebuloni M, Santovito ML, et al. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Ann Neurol. 2004;55:687-694.
15. Sidenius N, Nebuloni M, Sala S, et al. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. J Neuroimmunol. 2004;157:133-139.
16. Alfano M, Sidenius N, Panzeri B, Blasi F, Poli G. Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proc Natl Acad Sci U SA. 2002;99:8862-8867.
17. Elia C, Cassol E, Sidenius N, et al. Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion. J Leukoc Biol. 2007;82:1212-1220.
18. Granowitz EV, Saget BM, Wang MZ, Dinarello CA, Skolnik PR. Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein type 1. Mol Med. 1995;1:667-677.
19. Folks T, Benn S, Rabson A, et al. Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci U SA. 1985;82:4539-4543.
20. Folks TM, Clouse KA, Justement J, et al. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A. 1989;86:2365-2368.
21. Maslin CL, Kedzierska K, Webster NL, Muller WA, Crowe SM. Transendothelial migration of monocytes: the underlying molecular mechanisms and consequences of HIV-1 infection. Curr HIV Res. 2005;3:303-317.
22. Sankaran S, George MD, Reay E, et al. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J Virol. 2008;82:538-545.
23. Weeks BS. The role of HIV-1 activated leukocyte adhesion mechanisms and matrix metalloprotein-ase secretion in AIDS pathogenesis. Int J Mol Med. 1998;1:361-366.
24. Pomerantz RJ, Feinberg MB, Trono D, Baltimore D. Lipopolysaccharide is a potent monocyte/mac-rophage-specific stimulator of human immunodeficiency virus type 1 expression. J Exp Med. 1990;172:253-261.
25. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science. 1989;244:575-577.
26. Rizzi C, Crippa MP, Jeeninga RE, et al. Pertussis toxin B-oligomer suppresses IL-6 induced HIV-1 and chemokine expression in chronically infected U1 cells via inhibition of activator protein 1. J Immunol. 2006;176:999-1006.
27. Mengozzi M, De Filippi C, Transidico P, et al. Human immunodeficiency virus replication induces monocyte chemotactic protein-1 in human macro-phages and U937 promonocytic cells. Blood. 1999;93:1851-1857.
28. Fernie BF, Poli G, Fauci AS. Alpha interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphocytic cells. J Virol. 1991;65: 3968-3971.
29. Cubellis MV, Nolli ML, Cassani G, Blasi F. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem. 1986; 261:15819-15822.
30. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasmino-gen activator and its receptor. Curr Pharm Des. 2003;9:1499-1528.
31. Koshelnick Y, Ehart M, Stockinger H, Binder BR. Mechanisms of signaling through urokinase receptor and the cellular response. Thromb Hae-most. 1999;82:305-311.
32. Skretting G, Torgersen ML, van Deurs B, Sandvig K. Endocytic mechanisms responsible for uptake of GPI-linked diphtheria toxin receptor. J Cell Sci. 1999;112(Pt 22):3899-3909.
33. Picone R, Kajtaniak EL, Nielsen LS, et al. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol. 1989;108:693-702.
34. Stillfried GE, Saunders DN, Ranson M. Plasmino-gen binding and activation at the breast cancer cell surface: the integral role of urokinase activity. Breast Cancer Res. 2007;9:R14.
35. Clouse KA, Powell D, Washington I, et al. Mono-kine regulation of human immunodeficiency vi-rus-1 expression in a chronically infected human T cell clone. J Immunol. 1989;142:431-438.
36. Goletti D, Kinter AL, Biswas P, Bende SM, Poli G, Fauci AS. Effect of cellular differentiation on cyto-kine-induced expression of human immunodeficiency virus in chronically infected promonocytic cells: dissociation of cellular differentiation and viral expression. J Virol. 1995;69:2540-2546.
37. Goletti D, Kinter AL, Hardy EC, Poli G, Fauci AS. Modulation of endogenous IL-1 beta and IL-1 receptor antagonist results in opposing effects on HIV expression in chronically infected monocytic cells. J Immunol. 1996;156:3501-3508.
38. Simon DI, Ezratty AM, Francis SA, Rennke H, Loscalzo J. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a nonplasmin fibrinolytic pathway. Blood. 1993;82:2414-2422.
39. Kugler MC, Wei Y, Chapman HA. Urokinase receptor and integrin interactions. Curr Pharm Des. 2003;9:1565-1574.
40. Feldhaus MJ, Kessel JM, Zimmerman GA, McIntyre TM. Engagement of ICAM-3 activates polymorphonuclear leukocytes: aggregation without degranulation or beta 2 integrin recruitment. J Immunol. 1998;161:6280-6287.
41. Graham IL, Gresham HD, Brown EJ.An immobile subset of plasma membrane CD11b/CD18 (Mac-1) is involved in phagocytosis of targets recognized by multiple receptors. J Immunol. 1989; 142:2352-2358.
42. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost. 2007;97:336-342.
43. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active anti-retroviral therapy. J Med Virol. 2008;80:209-216.
44. Ostrowski SR, Katzenstein TL, Piironen T, Gerstoft J, Pedersen BK, Ullum H. Soluble urokinase receptor levels in plasma during 5 years of highly active anti-retroviral therapy in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35:337-342.
45. Pawlak K, Mysliwiec M, Pawlak D. The uroki-nase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemo-kines in uraemic patients. Thromb Res. 2008;122:328-335.
46. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. suPAR associates to glucose metabolic aberration during glucose stimulation in HIV-infected patients on HAART. J Infect. 2008;57:55-63.
47. Alfano M, Poli G. Role of cytokines and chemo-kines in the regulation of innate immunity and HIV infection. Mol Immunol. 2005;42:161-182.
48. Yang X, Chen Y, Gabuzda D. ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappa B. J Biol Chem. 1999;274: 27981-27988.
49. Wada M, Wada NA, Shirono H, Taniguchi K, Tsuchie H, Koga J. Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication. Biochem Biophys Res Com-mun. 2001;284:346-351.
50. Resnati M, Pallavicini I, Wang JM, et al. The fibrino-lytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A. 2002;99:1359-1364.
51. Ross GD. Role of the lectin domain of Mac-1/CR3 (CD11b/CD18) in regulating intercellular adhesion. Immunol Res. 2002;25:219-227.
52. Sitrin RG, Pan PM, Srikanth S, Todd RF 3rd. Fi-brinogen activates NF-kappa B transcription factors in mononuclear phagocytes. J Immunol. 1998;161:1462-1470.
53. Bouhlal H, Galon J, Kazatchkine MD, Fridman WH, Sautes-Fridman C, Haeffner Cavaillon N. Soluble CD16 inhibits CR3 (CD11b/CD18)-mediated infection of monocytes/macrophages by opsonized primary R5 HIV-1. J Immunol. 2001;166:3377-3383.
54. Thieblemont N, Haeffner-Cavaillon N, Haeffner A, Cholley B, Weiss L, Kazatchkine MD. Triggering of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappa B (p50/p65) in human monocytes and enhances viral replication in HIV-infected mono-cytic cells. J Immunol. 1995;155:4861-4867.
55. Stoiber H, Speth C, Dierich MP. Role of complement in the control of HIV dynamics and patho-genesis. Vaccine. 2003;21(Suppl 2):S77-S82.
56. Khayat D, Soubrane C, Andrieu JM, et al. Changes of soluble CD16 levels in serum of HIV-infected patients: correlation with clinical and biologic prognostic factors. J Infect Dis. 1990;161: 430-435.
57. Stoiber H, Frank I, Spruth M, et al. Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry? Mol Immunol. 1997;34:855-863.
58. Shattock RJ, Friedland JS, Griffin GE. Release of human immunodeficiency virus by THP-1 cells and human macrophages is regulated by cellular adherence and activation. J Virol. 1993;67:3569-3575.
59. Shattock RJ, Griffin GE. Cellular adherence enhances HIV replication in monocytic cells. Res Virol. 1994;145:139-145.
60. Fan ST, Hsia K, Edgington TS. Upregulation of human immunodeficiency virus-1 in chronically infected monocytic cell line by both contact with endothelial cells and cytokines. Blood. 1994;84: 1567-1572.
61. Simon DI, Wei Y, Zhang L, et al. Identification of a urokinase receptor-integrin interaction site: promiscuous regulator of integrin function. J Biol Chem. 2000;275:10228-10234.
62. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol. 1999;144:1285-1294.
63. Todd RF 3rd, Petty HR. Beta 2 (CD11/CD18) inte-grins can serve as signaling partners for other leukocyte receptors. J Lab Clin Med. 1997;129:492-498.
64. Madsen CD, Sarra Ferraris GM, Andolfo A, Cunningham O, Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol. 2007;177:927-939.
65. Petzinger J, Saltel F, Hersemeyer K, et al. Uroki-nase receptor (CD87) clustering in detergent-insoluble adhesion patches leads to cell adhesion independently of integrins. Cell Commun Adhes. 2007;14:137-155.
66. Wilflingseder D, Stoiber H. Float on: lipid rafts in the lifecycle of HIV. Front Biosci. 2007;12:2124-2135.
67. Biswas P, Poli G, Kinter AL, et al. Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells. J Exp Med. 1992;176:739-750.
68. Fantuzzi L, Spadaro F, Vallanti G, et al. Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte-derived macrophages. Blood. 2003;102:2334-2337.
69. Ono A, Freed EO. Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicu-lar body. J Virol. 2004;78:1552-1563.
70. Deneka M, Pelchen-Matthews A, Byland R, Ruiz-Mateos E, Marsh M. In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. J Cell Biol. 2007;177:329-341.
71. Welsch S, Keppler OT, Habermann A, Allespach I, Krijnse-Locker J, Krausslich HG. HIV-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathog. 2007;3:e36.
72. Cassol E, Alfano M, Biswas P, Poli G. Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence. J Leukoc Biol. 2006;80:1018-1030.
73. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M. The role of mono-nuclear phagocytes in HTLV-III/LAV infection. Science. 1986;233:215-219.
74. Gendelman HE, Orenstein JM, Martin MA, et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med. 1988;167:1428-1441.
75. Folks TM, Justement J, Kinter A, et al. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol. 1988;140:1117-1122.
76. Orenstein JM, Jannotta F. Human immunodeficiency virus and papovavirus infections in acquired immunodeficiency syndrome: an ultra-structural study of three cases. Hum Pathol. 1988;19:350-361.